IPRATROPIUM BROMIDE
NASAL ANTICHOLINERGICS · CHRONIC NON-ALLERGIC RHINITIS ·+2
OCEANSIDE PHARM
Drug class
Nasal Anticholinergics
Nasal anticholinergics are topically administered parasympatholytic medications, exemplified by intranasal ipratropium bromide, designed to manage excessive nasal secretions. Read more about Nasal Anticholinergics
10 drugs in this class 10 manufacturers
Drugs in Nasal Anticholinergics
Filter & compare in the drug finder →
Opens the drug finder with Nasal Anticholinergics preselected. Add indication or manufacturer filters there.
Nasal anticholinergics are topically administered parasympatholytic medications, exemplified by intranasal ipratropium bromide, designed to manage excessive nasal secretions.
They function by competitively antagonizing muscarinic acetylcholine receptors on serous and seromucous glands within the nasal mucosa, thereby inhibiting parasympathetically mediated hypersecretion.
Clinically, these agents provide targeted symptomatic relief for severe rhinorrhea associated with allergic rhinitis, nonallergic perennial rhinitis (vasomotor rhinitis), and the common cold.
Because their therapeutic activity is localized and systemic absorption is minimal, they control anterior rhinorrhea without significantly altering other rhinitis symptoms like nasal congestion or sneezing.
-
nih.gov
Nasal anticholinergics are topically administered parasympatholytic medications, exemplified by intranasal ipratropium bromide, designed to manage excessive nasal secretions They function by competitively antagonizing muscarinic acetylcholine receptors on serous and seromucous glands within the nasal mucosa, thereby inhibiting parasympathetically mediated hypersecretion Clinically, these agents provide targeted symptomatic relief for severe rhinorrhea associated with allergic rhinitis, nonallerg...
-
nih.gov
Nasal anticholinergics are topically administered parasympatholytic medications, exemplified by intranasal ipratropium bromide, designed to manage excessive nasal secretions They function by competitively antagonizing muscarinic acetylcholine receptors on serous and seromucous glands within the nasal mucosa, thereby inhibiting parasympathetically mediated hypersecretion Clinically, these agents provide targeted symptomatic relief for severe rhinorrhea associated with allergic rhinitis, nonallerg...
-
fda.gov
Clinically, these agents provide targeted symptomatic relief for severe rhinorrhea associated with allergic rhinitis, nonallergic perennial rhinitis (vasomotor rhinitis), and the common cold Because their therapeutic activity is localized and systemic absorption is minimal, they control anterior rhinorrhea without significantly altering other rhinitis symptoms like nasal congestion or sneezing
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.